Michael joined Brandon Capital in 2016.
Before joining Brandon Capital, Michael was Senior Business Development Manager at Monash University, where he managed the Life Sciences portfolio for the Faculty of Medicine. He led the commercialisation of multiple technologies, that have resulted in licensing agreements with organisations ranging from global pharmaceutical companies such as Hoffmann‑La Roche to emerging biotechnology companies such as ArsenalBio.
Earlier in his career, Michael was an Investment Manager (Life Sciences) at TTCF, a seed and venture commercialisation fund focused on academic research–driven innovation. He led due diligence and negotiations for several life sciences investments, including Nexvet Biopharma (NASDAQ: NVET), acquired by Zoetis in 2017. Nexvet’s lead monoclonal antibody asset (now marketed as Solensia) was projected by Zoetis to exceed US$500 million in peak annual revenue.
Michael’s research background includes a Roche Research Foundation Postdoctoral Fellowship at ISREC (EPFL) in Lausanne, Switzerland. He holds a Bachelor of Science (First‑Class Honours) and a PhD in stem cell biology from the University of Adelaide, as well as an MBA in Technology Management from La Trobe University. He is a graduate of the Australian Institute of Company Directors (AICD).
Michael is a Director of Cincera Therapeutics Pty Ltd, Foray Therapeutics Pty Ltd, Mirugen Pty Ltd and Currus Biologics Pty Ltd. He also led due diligence for the firm’s recent investment in AdvanCell Isotopes Pty Ltd.
